Yogish Kudva
Endocrinology, Diabetes & Metabolism · Rochester, MNNPI 1073586137
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $30,211 of the $37,697 with a category attached, or 80.1%. Novo Nordisk accounts for 61.1% of it on its own, with 8 other manufacturers making up the rest. 2025 is the largest year on record at $15,877, more than ten times the $14 reported in 2019.
Across 47 payments — averaging $802.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$23K
- Vertex$11K
- Nestle Healthcare Nutrition Inc.$2K
- E.r. Squibb & Sons, L.L.C.$1K
- Sanofi-aventis U.S. LLC$388
- Medtronic$270
- plus $270 from 3 others
Across 774 payments — averaging $3742.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$1.2M
- Dexcom, Inc.$712K
- Tandem Diabetes Care, Inc.$494K
- Sequel Med Tech, LLC$211K
- Mannkind Corporation$168K
- Novo Nordisk AS$89K
- plus $49K from 1 others
What the payments were for
- Consulting fees$30,21180%
- Travel & lodging$5,34314%
- Food & beverage$2,1006%
- Gifts$430%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 17 | $23,040 |
| Vertex | 15 | $10,778 |
| Nestle Healthcare Nutrition Inc. | 1 | $1,800 |
| E.r. Squibb & Sons, L.L.C. | 1 | $1,150 |
| Sanofi-aventis U.S. LLC | 4 | $388 |
| Medtronic(2 entities) | 3 | $270 |
| Mannkind Corporation | 4 | $161 |
| Tandem Diabetes Care, Inc. | 1 | $71 |
| Dexcom, Inc. | 1 | $38 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tresiba$12,457
- ZENPEP$1,800
- TZIELD$334
- MINIMED 780G$146
- Minimed 670G System$109
How this compares
$37,697 in reported general payments places this provider in the 85th percentile of 120 endocrinology, diabetes & metabolism providers in Minnesota.
See all endocrinology, diabetes & metabolism providers in Minnesota →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 60 | $72,703 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 33 | $45,724 |
| MounjaroTirzepatide | 35 | $44,267 |
| TrulicityDulaglutide | 21 | $20,920 |
| FarxigaDapagliflozin Propanediol | 11 | $18,464 |
| JardianceEmpagliflozin | 11 | $14,654 |
| Tresiba Flextouch U-100Insulin Degludec | 30 | $12,297 |
| NovologInsulin Aspart | 26 | $9,471 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $6,458 |
| Novolog FlexpenInsulin Aspart | 15 | $5,241 |
| HumalogInsulin Lispro | 23 | $5,204 |
| Tacrolimus | 27 | $3,526 |
| Ezetimibe | 54 | $1,426 |
| LantusInsulin Glargine,hum.Rec.Anlog | 12 | $1,341 |
| Mycophenolate Mofetil | 11 | $952 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $23,040 | $82,17486 claims |
| Sanofi-aventis U.S. LLCLantus | $388 | $1,34112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 120 endocrinology, diabetes & metabolism providers in Minnesota.
Other endocrinology, diabetes & metabolism in Rochester
- Marjorie Ann MalbasRochester$222K
- Irina BancosRochester$114K
- Maria CastroRochester$63K
- Marius StanRochester$59K
- Matthew DrakeRochester$41K
- Manpreet MundiRochester$39K
- Bart ClarkeRochester$36K
- Robert RizzaRochester$30K
- Adrian VellaRochester$26K
- Michael JensenRochester$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.